Additional Relevant Details 75 Percent of Patients Achieved Rapid and Reliable Hemostasis within Three Minutes When Treated with EVARREST, Compared to 45 Percent Treated with TachoSil

Results from this investigational study will be presented at The Houston Aortic Symposium.
In the intent-to-treat primary endpoint analysis, 57 of 76 (75%) of patients treated with EVARREST achieved hemostasis within three minutes of product application. Hemostasis was maintained through the initiation of chest wall closure. Thirty six of 80 (45%) of those treated on the TachoSil arm achieved the primary endpoint. In the secondary endpoint analysis, 77.6% and 84.2% of patients treated with EVARREST achieved hemostasis at six minutes and ten minutes, respectively, and maintained hemostasis through initiation of chest wall closure. In the TachoSil arm, 56.3% and 70% of patients achieved hemostasis at six minutes and ten minutes, respectively, and maintained hemostasis through initiation of chest wall closure.No major safety concerns were identified during the study.